Global Surgical Power Tools Market Size, Status and Forecast 2021

Surgical power tools market is currently experiencing a shift from traditional pneumatic tools to new technology electric power tools. Electric and battery powered tools are durable and provide precision during procedures. Development in designs has helped in expanding the scope of application in orthopedic procedures, dental surgeries, ENT procedures and neurosurgeries. Surgical power tools are used for gaining access to surgical sites, shaping bones to efficiently fit implants, and repositioning. Incidences of trauma, increasing demand for joint replacement, and dental cosmetic procedures are some of the factors driving the surgical power tools market.

New technology surgical tools have ergonomic designs allowing better comfort and precision for surgeons. Light weight, curved handles and improved hand piece texture improves grip, thus minimizing surgical errors. Disposable surgical power tools are gradually becoming popular owing to cost efficiency and reduced chances of contamination. These devices are ideal for hospitals with less sophisticated sterilization equipment. Being single use, it becomes easier for hospital management to maintain assets, and escape sterilization schedules. Disposable power tools also act as a backup for mainstream devices, and avoid delay during sudden breakdown and emergencies. No large capital investment and service agreements are required, that makes disposables as best alternative in terms of cost efficiency. Due to these merits, large hospitals are giving increased importance to disposable tools.

Request Free Report Sample@–Forecast-2017-2021/up118

Asia Pacific and Latin America has become a prime destination for surgical power tools market in the recent past. Major factor driving the market in the region is the trend for medical tourism. Joint replacement surgeries can be performed in these regions in over half the cost in the U.S. Indian High Commission states that 18,000 Nigerians visited India on medical visas in 2014. Secretary of Tourism, Mexico recorded over 6.5 million visitors from the U.S for medical treatment in 2013. Thailand, Singapore, South Korea, Malaysia and India are key destination in Asia Pacific region. Taiwan Ministry of Health and Welfare also found that 50% of the patients traveling to the country for medical treatment came from China in 2012. Due to these factors the surgical power tools market is expected to grow rapidly in Asia Pacific and Latin America region.

The surgical power tools market is fragmented with more than 20 players operating at global as well as local level. Well established distribution channels and subtle differentiation in product portfolio makes the market competitive. Top five players in the market include Conmed, Stryker, Zimmer Biomet, DePuy Synthes, and Medtronic; while other prominent players include Arthrex, B. Braun, Aesculap, Aedor and Aygun.

Request For TOC@–Forecast-2017-2021/upcomingdetail118

NOTE: This report is currently under research and will be made available to clients on request.


Global Hearing Aids Market – Product Segment Analysis And Forecast

The “Global Hearing Aids Market Assessment & Forecast 2017-2021”, estimates that the global hearing aids market was valued at US$ 7,116.3 million in 2016 and is forecast to reach US$ 9,217.0 million by 2021 at a CAGR of 4.1% from 2017 to 2021.

Asia Pacific is expected to be the most profitable hearing aids market. India and China are two most highly populated countries globally and account for larger geriatric population along with countries such as Japan. Percentage of population above 65 years of age in U.S. is 14.7% as against 9.5% in China and 5.6% in India. However this percentage translates to 47.2 million in U.S., 130.2 million in China and 73.4 million in India. 26.3% of Japan’s population is aged 65 years and above; highest globally. In spite of such large patient pool, Asia Pacific currently accounts for less than 20% of the global market. Major reason impeding the adoption of hearing aid were ignorance to hearing loss and high cost of hearing aids that are not covered by insurance providers. Due to economic developments, the per capita income has increased in major Asia Pacific economies. This financial support would drive the hearing aids market in Asia Pacific region.

Request Free Report Sample@–Forecast-2017-2021/sample38

The report also provides market estimation by type of hearing aids that includes receiver-in-canal (RIC), behind-the-ear (BTE), in-the-ear (ITE), in-the-canal (ITC), completely-in-canal (CIC) and hearing aids consumables and accessories. RIC hearing aids stands out as a leading segment on account of long standing market and higher popularity across the globe. Wireless RIC devices are expected to completely replace non-wireless devices the near future. ITEs accommodate larger batteries as compared to ITC and CTC as they are comparatively larger in size. ITCs and CTCs also cannot accommodate telecoils due to their smaller size.

Key players in the global hearing aids market include Sonova, William Demant, Sivantos, GN Hearing, Starkey and Widex. Other players operating at local as well as global level include Zounds, Microson, Audina, ExSilent, IntriCon and Ear Teknik.

Go For Report TOC And More@–Forecast-2017-2021/38

Hyperbaric Oxygen Therapy (HBOT) Market Assessment, Size and Forecast Till 2021

Hyperbaric oxygen therapy involves a pressurized room or tube in which patients are exposed to oxygen enriched environment. Breathing pure oxygen is known to treat a variety of illnesses and conditions such as decompression sickness, altitude sickness, anemia, arterial gas embolism, chronic wounds, radiation injury, burns and CO gas poisoning. Hyperbaric treatment enhances the body’s healing process as hemoglobin enriched with oxygen can reduce tissue necrosis and promote healing factors. The oxygen molecules decrease in size as they are in a pressurized environment and are able to dissolve into the blood plasma.

This report estimates the market for Hyperbaric oxygen therapy (HBOT) therapy in terms of value ($ millions) and provides analysis of upcoming treatment application areas. The report covers monoplace, multiplace and topox HBOT technologies. Topical oxygen, or Topox, is administered through a small chamber or device placed over an extremity or a body part and pressurized with oxygen. The patient does not breathe the oxygen, rather the particular portion of the body is exposed to pure oxygen. This treatment is not systemic but helps with external wounds and burns. Altitude and decompression sickness are often observed among climbers and scuba divers. A scientific study by Dauphin Island Sea Lab yielded an overall incidence of DCI to be 0.93/10,000 person-dives for recreational, instructional/guided, commercial and/or military diving. However, HBOT finds significant applications in treatment of carbon monoxide poisoning and burn victims and greatest in treatment of gangrene and chronic wounds. The growing incidence of chemical burns and fire burns across the world has diverted the attention of the market to growing applications of topical HBOT. Hyperbaric oxygen therapy (HBOT) market by end-users is divided into three major entities; hospitals, private settings, commercial diving industry, nursing facilities and other government institutional facilities.

Free Report Sample@–Forecast-2017-2021/up113

The report will enable for HBOT clinics to estimate the risks, competition and market dynamics in order to expand to other medical conditions that show benefits of HBOT to a certain degree; although they considered off-label indications. The hyperbaric oxygen therapy devices market is clustered in western hemisphere primarily due to greater adoption, awareness and accessibility. Notable players include OxyHealth LLC, ETC Biomedical, Gulf Coast Hyperbarics, Sechrist Industries, Perry Baromedical, BaroxHBO and SMP Ltd (UK).

NOTE: This report is currently under research and will be made available to clients on request.

Request For Report TOC@–Forecast-2017-2021/upcomingdetail113

Global Aptamers Market Size, Status and Forecast 2021

Aptamers are oligonucleotides or peptide bioreceptors that can selectively bind to specific molecular targets with high affinity. Aptamers have proved to be an excellent alternative to monoclonal antibodies. Due to its properties, aptamers have found application in therapeutic drug development, diagnostics, and biotechnology research and development. Aptamers are non-immunogenic, non-toxic and also have fewer side effects as compared to monoclonal antibodies because of the absence of Fc region. Smaller size permits easy entry of aptamers into the target cells and increases efficiency at lower concentrations. Due to their thermal stability, aptamers remain viable during transport and storage. Moreover aptamers are manufactured through chemical synthesis process hence have lower cost of production. This also allows easy scale-up of manufacturing process that is very difficult with monoclonal antibodies. These factors have made aptamers as excellent candidates for therapeutic drug development.

Various research institutes and pharma companies are conducting rigorous research for development of aptamers cancer treatment. Numerous companies have invested heavily in aptamers drug development. AptaTargets a Spanish biopharmaceutical company raised over US$ 3 million in funding in May 2017. The company plans to use these finds for conducting preclinical phase and advance into phase I and phase II clinical trials on its first drug candidate ApTOLL that is targeted for treatment of acute ischemic stroke. NOXXON and Anisoma are other key companies involved in therapeutic aptamers research. With increasing research and development activities and scientific publications advocating importance of aptamers in therapeutics, companies specializing in large scale aptamer manufacturing have emerged in the recent past. This has boosted the contract manufacturing organization (CMO) business. Currently systematic evolution of ligands by exponential enrichment (SELEX) method is widely used for aptamer synthesis. Although various modified versions of the parent method have evolved, it is expected that more productive and cost effective alternatives would emerge in the future. This would fuel the global aptamers market.

Request Free Report Sample@–Forecast-2017-2021/up115

Discovery of biomarkers that play important role in disease progression has contributed immensely to development of target therapy. Diseases such as cancer, autoimmune diseases, viral diseases, cardiac disorders and neurology disorders have been main attraction for development of aptamer targeted therapy. Aptamers are forecast to become an inevitable part of targeted therapy in the near future. Treatment of viral infections is an emerging application of aptamers; however majority of the research is focused on human immunodeficiency virus (HIV), Hepatitis C virus (HCV), and Hepatitis B virus (HBV).

Key players in the aptamers market include NOXXON Pharma AG, Ophthotech Corp, Archemix (Baxter), NeXstar (Gilead), AptaMatrix, Aptus Biotech, Base Pair Biotechnologies and Vivonics among others.

Request For TOC@–Forecast-2017-2021/upcomingdetail115

NOTE: This report is currently under research and will be made available to clients on request.

RF Ablation Devices For Dermatology And Cosmetology Market Was Valued At USD 134.4 Mn In 2016

LogoSA-BRC announces the release of market assessment report on “Global Radiofrequency Ablation Devices for Dermatology & Cosmetology Market Assessment & Forecast 2017-2021

The “Global Radiofrequency Ablation Devices for Dermatology & Cosmetology Market Assessment & Forecast 2017-2021”, estimates that the global radiofrequency ablation devices for dermatology & cosmetology market was valued at US$ 134.4 million in 2016 and expected to grow to US$ 221.0 million by 2021 at a CAGR of 7.8% from 2017 to 2021.

Skin tightening and rejuvenation is one of the most popular cosmetic procedures globally. With aging population and trend for ‘social media sharing’ large percentage of baby boomers are opting for skin rejuvenation procedures. Although injectables continue to be preferred alternative, patients are gradually shifting towards non-surgical treatments to avoid side effects. Global facial injectable procedures increased over 50% from 5,146,446 in 2010 to 7,730,464 in 2015, while non-surgical skin tightening procedures increased by 105% from 165,732 in 2010 to 340,609 in 2015 according to International Survey on Aesthetic/Cosmetic Procedures performed in 2015.

Request Free Report Sample@–Cosmetology-Market-Assessment–Forecast-2017-2021/sample37

Radiofrequency skin rejuvenation market is competitive with over 15 players. Thermage by Solta (Valeant Pharmaceuticals) is a leading product in this segment. Large numbers of local players also exist in the market; however these players are more active in South East Asian countries where regulatory policies are less stringent. Microneedling has been used in cosmetic procedures for a long time, however the technology has gained increased adoption only recently. With growing number of players such as Ilooda, Lutronic, Lumenis, Jeisys, Inmode/Invasix and EndyMed the microneedling market is anticipated to grow significantly in the future driving the RF technology in aesthetics further. Medical tourism is the key factor driving RF ablation devices market in dermatology and cosmetology in the Asia Pacific region. Thailand, Singapore, South Korea, Malaysia and India are key destination in Asia Pacific region. North America and Europe account for a combined share of 63% in terms of value, although this share is expected to drop to 61% by 2021.

The report also segments the market by end-users that include hospitals and dermatology and cosmetology clinics. From the point-of-view of geography North America, Europe, Asia Pacific, Latin America and Middle East and Africa (MEA). The report also provides market share analysis of more than 10 players in the global market place, and mentions over 20 players marketing RF ablation devices for dermatology and cosmetology. Some of the key players in the market include Lumenis (Pollogen), Aesthetics Biomedical Inc., Alma Lasers, BTL Aesthetics, Almirall, F-Care Systems, Valeant Pharmaceuticals (Solta Medical) and various others.

More Report Description And TOC@–Cosmetology-Market-Assessment–Forecast-2017-2021/37

U.S. Leads The Overall Facial Injectable Market

LogoGrowing popularity of minimally invasive cosmetic surgeries and increasing disposable income has led to substantial growth in the overall cosmetic procedures market. Facial injectable are generally used for skin rejuvenation, reduction or elimination of dark spots and wrinkles, and lip enhancement. The market for facial injectables has been broadly segmented as follows:

  • Botulinum Toxin
  • Hyaluronic Acid
  • Collagen
  • Polymers and Particles
  • Dermal Fillers

Hyaluronic acid and poly-L-lactic acid (PLLA) are commonly used long lasting facial injectable products which are reported to last from 10 months to 15 months depending on injection site. Restylane (Gladrma) and Juvederm (Allergan) are most popular hyaluronic acid facial injectable brands worldwide. Botulinum toxin marketed under brand names Botox (Allergan) and Dysport (Gladerma) is also one of the long standing products in the market. According to The American Academy of Facial Cosmetics, Botulinum toxin procedures for facial rejuvenation are increasing at a rate of about 4.5% annually in the U.S. Furthermore, statistics published by the American Society of Plastic Surgeons states that between 2013 and 2014, hyaluronic acid (HA) filler treatments had increased by over 8%.

Request Free Report Sample@–Forecast-2017-2021/up43

The global facial injectables market is highly competitive, and dominated by few global players. U.S. leads the overall facial injectable market; however the market is rapidly growing in South-East Asian countries owing to increasing trend for medical tourism. In the recent past there has been a surge of counterfeit products circulating in the Asian market. In 2013, ShanghaiDaily published that some patients had approached physicians with complaints of swollen face after using Botox products purchased online at substantially lower costs. In China, Hongli (Lanzhou Institute of Biological Products) and Botox (Allergan) are the only approved botulinum toxin brands. To tap lucrative market opportunity in the facial injectables market, various fake treatment centers have also emerged in this region.

In October 2013, Allergan announced that Juvederm Voluma XC was approved in the U.S. as the first and only dermal filler for deep injection to temporarily correct age-related volume loss in the cheek area in adults over the age of 21. Cosmetic Botox accounted for 15% share in the company’s revenue in 2013. In 2014, Gladerma (Nestle S.A.) announced that it entered into an agreement with Valeant Pharmaceuticals International, Inc. to gain full commercialization rights for Restylane, Perlane, Emervel, Sculptra and Dysport for use in aesthetic dermatology in the U.S. and Canada. These events have changed the global facial injectable market place. Zyderm, Sculptra, Captique, Hylaform, Artefill are other brands competing in the market.

Request For TOC@–Forecast-2016—2020/upcomingdetail43

NOTE: This report is currently under research and will be made available to clients on request.

North America and Europe Bionic Eye Market Assessment Till 2021

LogoSudden surge in bionic eye market was experienced recently after the National Health Service (NHS) announced the sponsorship to implant bionic eyes in ten patients. The bionic eye can help regain vision in individuals with visual impairment. Although currently two bionic eye systems has received regulatory approvals, other companies in the bionic eye market are also trying to develop new technology that can help in regaining visual sense in patients.

The Argus II Retinal Prosthesis System developed by Second Sight consists of a miniature camera mounted on patient’s glasses. This camera is connected to a video processing unit (VPU) which processes the information. This information is transmitted wirelessly to a retinal implant that helps in visualizing objects. The company claims that the implant helps in resorting vision to an extent that the patient can identify shapes. The company also plans to upgrade the current version to improve vision quality. The device had received regulatory clearance in 2013 to address adult patients with advanced retinitis pigmentosa (RP), rare genetic eye disease. Pixium Vision was awarded CE market for its IRIS II bionic vision system in 2016. The company recently completed its first implantation and activation of IRIS II in Spain. Bionic eye market comprises only these two systems that have received regulatory approval, while other products in pipeline would need more incubation for development.

Request Free Report Sample@–Forecast-2017-2021/up90

Boston Retinal Implant Project (BRIP), an organization based in the U.S. is developing retinal prosthesis to enhance visibility. Monash University, Australia is also conducting research on development of bionic eye systems that can enable visual sense at some level to individuals who are completely deprived of eyes. Such research and development would introduce more refined products in the bionic eye market. Although currently research in bionic eye market is in a nascent stage, advances in nanotechnology and deeper understanding of human diseases would reveal new ground for further research.

It is estimated that over 1 million individuals globally of which more than 0.3 million individuals in North America and Europe suffer from Retinitis Pigmentosa. Blindness is also a major concern with over 285 million individuals being visually impaired globally. The reasons for blindness are varied ranging from rare genetic diseases to life style diseases such as diabetes. Cataract affects more than 20 million people, and is responsible for 50% of the global visionless population. According to American Academy of Ophthalmology, U.S., cataract affects more than 22 million people with age 40 years and above. It is also estimated that over 3 million individuals in the U.S. suffer from glaucoma, while 50% of these cases are diagnosed only in later stages. Such high prevalence and ageing population which is a major predisposing factor for diseases leading to vision loss would drive the bionic eye market.

Request For TOC@–Forecast-2017-2021/upcomingdetail90

NOTE: This report is currently under research and will be made available to clients on request.

Good Growth Opportunities in Global Orthobiologics Market Till 2021

Business Analytics

Orthobiologics used for accelerating musculoskeletal injuries have witnessed increased demand in the recent past due to rapid developments in the market. Orthobiologics market is expanding globally due to introduction of newer products based on platelet rich plasma and stem cell technology. Orthobiologics utilize regenerative potential of the body and assist in quick recovery of patients. These products are widely used in orthopedic procedures for bone injury, soft tissue damage, spinal procedures, caranio maxillofacial procedures and others. With introduction of platelet rich plasma and stem cell therapy orthobiologics market has witnessed swift growth in other disease areas. Quicker adoption of viscosupplementation products, bone marrow concentrate and specific growth factors are other drivers for the market.

Currently autograft are most popular considering compatibility and lesser side effects. However, physicians often face dilemma in using autograft and allograft. Advantages of allograft include quick surgery time, and reduced donor site morbidity; however serious side effects disease transmission and rare availability subvert these merits. Body may also launch an immune response against the allograft which may lead to serious complications and may even lead to replacement of the allograft. Platelet rich plasma (PRP) has gained focus due to its increased acceptance in sports medicine. Therapeutic applications of PRP include chronic tendon injuries, ligament and muscle injuries, tissue healing in chronic injuries, and arthritis. However unapproved application of PRP in orthopedic procedures has raised serious concerns. Regulatory interference on use of PRP, and approvals of fewer products may encourage companies to invest more in PRP therapy.

Request Free Report Sample@–Forecast-2017-2021/up106

Increasing number of orthopedic procedures and soft tissue repair procedures globally has supported the orthobiologics market growth. Aging population, and growing trend for physical fitness among baby boomers has led to an increase in patient footfall at hospital and emergency rooms with musculoskeletal injuries. North America and Europe account for largest share of the orthobiologics market, while rapid growth is anticipated in Asia Pacific and Latin America region. Evolving hospital infrastructure, improving economic conditions, increase in awareness about newer medical technology and availability of skilled physicians are some of the factors driving the orthobiologics market in these regions. Healthcare sector in Middle East region is also evolving rapidly. Government has laid major focus on improving quality of medical care in UAE. Increasing number of hospitals and specialty centers has boosted the overall healthcare market in this region.

Stryker Corporation, Arthrex, Inc., Isto Biologics, Anika Therapeutics, Inc., RTI Surgical, Inc., DePuy Synthes (Johnson&Johnson), Lattice Biologics Ltd., SeaSpine, and Citagenix are some of the leading players in the global orthobiologics market.

Request For TOC@–Forecast-2017-2021/upcomingdetail106

NOTE: This report is currently under research and will be made available to clients on request.

Stem Cell Therapies Market Assessment And Outlook Till 2021

medical devicesStem cells are characterized by their potential to develop into fully functional cells of a specific organ or tissue in the body. Theoretically stem cells can be artificially coaxed into becoming a muscular cell, nerve cell or any other based on the medical requirement. This capability called “Totipotency” is sometimes lost along the development stages and cells then become pluripotent, multi-potent and oligopotent at each level. The stem cells of the body include embryonic stem cells, which are present in a blastocyst, fetal stem cells, cord blood stem cells (isolated from umbilical cord), adipose tissue, hematopoietic stem cells and dental stem cells. Stem cells and progenitor cells help act as a treatment and can perform as a damage repair mechanism of the body. Umbilical stem cells and embryonic stem cells can be stored in cryogenic-refrigeration as a stem cell storage bank for later use.

Stem cells have been applied in several therapies of late, particularly in oncology and brain disorders. The potential areas of stem cell therapy are limitless since the stem cells adapt to various body stimulus to convert into cells of unique function and type. This report covers the market for stem cell therapies, products and anti-bodies among other products in research pipelines of many key industrial players. The most common type of cells therapies commercialized today includes mesenchymal stem cells or MSCs. SCs used in osteo-grafting is one of the fastest growing market segments today. Research & development is carried out by government and private institutions on a very large scale since the success of even one application would mean the quickest means of treating severe and debilitating diseases and conditions. The most common proven treatments are targeted for bone, corneal and skin diseases. AMD in particular is a key target area within corneal treatments. BMT?s have been performed for over a decade successfully in most cases for autoimmune disorders, cancer and blood disorders among others. A rising application area is cosmetics wherein conditions such as alopecia are considered as strong growth factors.

Request Free Report Sample@–Forecast-2017-2021/up36

Ongoing research by SA-BRC estimates suggest the market to be valued at US$ 6.5 billion in 2014 and growing at a CAGR of 16.8%. The major drivers of this therapy are the increase in the stem cell banking and cord blood banking market, which has increased the number of stem cell procedures. The stem cell banking market is thus complementing the stem cell therapy market. Another factor driving the growth is the list of potential applications. Several challenges are currently preventing the use of stem cells particularly in western countries, where intense regulatory hurdles have resulted in the slow progress in treatment approvals unlike countries such as China, where stem cell therapies have received a greater acceptance by the government and are practiced on a larger scope of therapies. Reimbursement and cost of treatment is expected to be one of the most significant challenges to this market since ethical issues as well cost incurred to hospital for technology used to complete all stages of stem cell therapies. Since several therapies are not covered for by insurance, out-of-pocket expenses are enormous in most experimental cases.

Stem cell therapy is relatively an old research area in biopharmaceutical and biotechnology. There are an estimated 2 million research projects covering all aspects of stem cell research over the world. There are over 400 clinical trials being conducted across the world for SC therapy products. Thus, there are numerous players involved in stem cell products of which the most notable key players are companies such as Cytori, Cardio3 Bioscience, Bioheart, Aastrom Biosciences, Invitrogen (part of Life Technologies), Osiris Therapeutics, TiGenix and Gamida Cell. The competitive landscape is highly fragmented and is expected to remain so due to high number of emerging players in the market leading to a high level of threat from new entrants.

Request For TOC@–Forecast-2016—2020/upcomingdetail36

NOTE: This report is currently under research and will be made available to clients on request.

An Exclusive Healthcare Business Research and Consulting Company

Business AnalyticsSpearhead Acuity-Business Research & Consulting (SA-BRC) is a premium Life Science business intelligence and data analytics firm. SA-BRC team offers a wide range of business intelligence services to multiple stakeholders such as Medical Device Manufacturers, Service Providers (Hospitals, Payers, etc.), Suppliers, Group Purchase Organizations, Distributors and all other individuals in the entire value chain of healthcare industry. Our research and consulting capabilities extend across several sub-domains within the sphere of Life Sciences such as Biotechnology, Healthcare IT, Medical Devices, Veterinary Sciences, Wellness Products and Pharmaceuticals.

Services provided by SA-BRC

Syndicate Reports

A repository of market research studies conducted for instant access by our clients at a reasonable price. These reports comprise market data by valve/volume, sub-segments, applications, technologies, geographies, competitive landscape, etc.

Custom Reports (Client specific research)

Either an existing syndicate report is customized to suit the clients’ needs or a completely fresh and customized research is conducted as per the defined requirements from clients. We constantly engage and update our clients through provisional research deliverables to ensure right assessment and research target. We follow a robust research methodology to achieve high quality results which is an amalgamation of secondary and primary sources.

Competitive Intelligence

Major healthcare industry players (more than 50% of the top pharma and medical device manufacturers) are still hesitant in engaging with patients and other stakeholders in the value chain through social media channels. The returns on expenses meted out for social media tracking is difficult to directly equate with sales but definitely helps enhancing it in the long run.

Pharmaceutical Drug Analogue Based Forecasting Tool

The Pukka tool provides access to qualitative and quantitative (U.S. sales) data of over 100 brands for United States market with more brands being added every year. Comparison models frequently present inaccurate predictions if the brands being considered have multiple indications or if brands being considered are only top selling prescriptions, however Pukka considers only those drugs that are FDA approved for single indication only and comprises of both top selling brands as well as those performing below par thus presenting an extremely realistic view of the comparison result.

Pukka currently offers analog forecasting for major disease categories such as oncology, metabolic disorder, cardiovascular, central nervous system, skin disease, respiratory, pain management, hematology, urology, autoimmune and auto inflammatory diseases. The database also presents market revenue for United States from approval to 2015 and a forecast of sales to 2022 for all 100 brands! It provides qualitative information on over 36 parameters such as adherence, persistence, molecule, order of entry, efficacy rate, disease condition, clinical manifestation, treatment type, formulation type, orphan designation, pharmacologic class, indication, disease category, route of administration, indication specificity, days of therapy, dosing frequency, cost per day, reimbursement tier, current ownership and others. The market forecast has been estimated using the most accurate prediction systems using base values gathered from annual reports and patient based forecasting techniques.

Consulting Projects & Survey Data Analysis

Similar to our customized research services, we also provide full-fledged consulting services in the domain of healthcare and life sciences. Clients remain updated through provisional research deliverables to ensure research target points are achieved. A pilot survey with 5%-10% sample respondents is conducted to ensure that the questionnaire is robust enough to capture answers to all the questions.

Most of the consulting projects are focused on the following research areas:

  • Message Testing Studies with Prescribing Physicians
  • Perceptual Mapping
  • Unmet Need Analysis
  • Cost – Benefit Analysis
  • Pricing & Reimbursement Studies
  • Disease Assessment
  • Market Entry Strategy Studies

KOL Mapping

Though there has been addition to the list of parameters that guides doctor’s prescription pattern, influence of KOLs remains the most impactful of all these factors: years of practice, CMEs, journal meta-analysis articles, patient involvement, managed care activities. SA-BRC team helps our client with an excel spreadsheet deliverable that captures KOLs by geographies (regions & countries) alongside other parameters listed below:

KOL’s: Rank (based on the overall score) 

  1. Full Name
  2. Total Citation Score
  3. Total Journal Impact Factor Score
  4. Count and details of the research publications till date
  5. Count and details of Clinical Trials (in which the KOL is/was involved)
  6. Additional responsibilities and involvement such as:
  7. Editorial board head/member
  8. Influence on Medicare/Medicaid reimbursement policies/reforms
  9. Head/member of Patient Advocacy Groups
  10. Receiver of Awards/Grants/Honors
  11. Organization Name
  12. Geographic Location
  13. Contact Details:
  14. E-mail ID (Official/Personal)
  15. Contact Number (Office/Residence/Desk/Mobile)
  16. Other parameters as per specific client requirement

Social Media Analytics

Major healthcare industry players (more than 50% of the top pharma and medical device manufacturers) are still hesitant in engaging with patients and other stakeholders in the value chain through social media channels. The returns on expenses meted out for social media tracking is difficult to directly equate with sales but definitely helps enhancing it in the long run.

Health Economics & Outcome Research Assessment

HEOR plays a critical role in deciding the fate of drugs and medical device technologies across multiple parameters such as – price, efficiency, adverse reactions, availability, disease burden, QUALY measurements, etc. HEOR studies are considered basis for evaluating a drug/device’s impact on patients quality of life.

For Further Info Contact Us
Phone: +91-02041210872